As Novo Spars Over Semaglutide Capacity, Strides To Arm GLP-1 Generics Cos Ahead Of LoEs

Primed To Tap $60bn Opportunity

 
• By Vibha Ravi

Strides is to supply semaglutide and liraglutide to generics companies amid global capacity constraints and drug shortages, ahead of loss of exclusivity. An ability to make drug-device combinations has meant it has contracts for seven of the eight GLP-1 agonists, and counting

GLP-1Agonists - A representative image using Ozempic, Wegovy, Trulicity, Victoza, Mounjaro newspaper cuttings
Can CDMOs Help Address Shortage Of GLP-1 Agonists?

Roche’s protest over an acquisition of Catalent by Novo Holdings, Novo Nordisk’s parent, underscores the high stakes in an anti-obesity drug battle that is seeing competitors spar over limited global manufacturing capacity amid skyrocketing demand for glucagon-like peptide-1 (GLP-1) agonists.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Supply Chain

More from Therapy Areas

In Brief: Mosaic Gains Two Clinical-Stage Oncology Assets From Astex

 
• By Sushmita Panda

Mosaic Therapeutics has in-licensed two clinical-stage oncology assets from Astex Pharmaceuticals to develop proprietary combination therapies for hard-to-treat cancers. The deal includes up to a 22% equity stake for Astex, future revenue sharing, and a planned clinical study in 2026.

In Brief: Boehringer Ingelheim, Tessellate Bio Link For Precision Therapies For ALT Tumors

 
• By Sushmita Panda

In its first pharma collaboration, Tessellate Bio has inked a deal potentially worth more than €500m with Boehringer Ingelheim for therapies for ALT tumors.

In Brief: Bioxodes To Take Novel Hemorrhagic Stroke Drug Into Registrational Trial

 
• By Sushmita Panda

The Belgium-based firm will take the first-in-class drug, based on tick saliva, targets inflammation without increasing bleeding, into a Phase IIb trial is in preparation, supported by a new series B funding round.